Upstate Active Clinical Trials

Study Title:

(CA180372) A Phase II Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

What is the purpose of the study?

Treatment study to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia

Upstate Institutional Review Board (IRB) Number:

276417

Study/Protocol ID:

AALL1122

Study Phase:

II

Patient Age Group:

Children

Principal Investigator:

Karol H Kerr, MD

ClinicalTrials.Gov ID:

NCT01460160

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Beatriz Kovar
Phone: 315-464-7232
Email: kovarb@upstate.edu

Return to Previous Page || Search Again